CST, 72105T, FXR/NR1H4 (E4B8P) Mouse Monoclonal Antibody

Monoclonal Antibody for studying NR1H4. Validated for Western Blotting,Immunoprecipitation,Chromatin IP. Available in 2 sizes. Highly specific and rigorously validated in-house, FXR/NR1H4 (E4B8P) Mouse Monoclonal Antibody (CST #72105) is ready to ship. Product Usage Information For optimal ChIP results, use 10 μl of antibody and 10 μg of chromatin (approximately 4 × 10 6 cells) per IP. This antibody has been validated using SimpleChIP ® Enzymatic Chromatin IP Kits. Western Blotting: 1:1000 Immunoprecipitation: 1:200 Chromatin IP: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation, Chromatin IP Specificity / Sensitivity FXR/NR1H4 (E4B8P) Mouse Monoclonal Antibody recognizes endogenous levels of total FXR/NR1H4 protein. Species Reactivity: Human, Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human FXR/NR1H4 protein. Background The farnesoid X receptor (FXR/NR1H4) is a member of the nuclear hormone receptor superfamily and is a master regulator of bile acid synthesis. FXR/NR1H4 heterodimerizes with RXR-alpha upon activation by bile acids, which begins a regulatory cascade involving SHP and LRH-1 to control lipid homeostasis (1-5). FXR/NR1H4 has also been shown to be a critical regulator of glucose homeostasis (6,7). In addition to directly regulating genes, FXR/NR1H4 also plays a post transcriptional role in bile acid metabolism by transcribing the RNA-binding protein ZFP36L1, which in turn downregulates the key enzyme Cyp7a1 (8). Mutations in human FXR/NR1H4 have been shown to cause cholestasis and liver disease in neonatal patients (9). FXR/NR1H4 can also control Lgr5+ intestinal stem cell proliferation and its upregulation has been shown to inhibit colorectal cancer progression (10-12). Agonists against FXR/NR1H4 are being evaluated for various liver diseases and diabetes (13-16). Alternate Names BAR; Bile acid receptor; farnesoid X nuclear receptor; farnesoid X receptor; Farnesoid X-activated receptor; Farnesol receptor HRR-1; FXR; HRR-1; HRR1; MGC163445; NR1H4; Nuclear receptor subfamily 1 group H member 4; nuclear receptor subfamily 1, group H, member 4; PFIC5; Retinoid X receptor-interacting protein 14; RIP14; RXR-interacting protein 14 Specification REACTIVITY: H M SENSITIVITY: Endogenous MW (kDa): 55 Source/Isotype: Mouse IgG2a